迈威生物：预计2025年净亏损9亿元-9.95亿元

Core Viewpoint - The company, Maiwei Biotech, is expected to continue incurring losses in 2025, with projected net losses ranging from 900 million to 995 million yuan, compared to a loss of 1.044 billion yuan in the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is expected to be a loss of 900 million to 995 million yuan, while the net profit after deducting non-recurring gains and losses is anticipated to be a loss of 905 million to 999 million yuan [1] - In the previous year, the company reported a net loss of 1.044 billion yuan attributable to the parent company, with a net loss of 1.07 billion yuan after excluding non-recurring items [1] Revenue Growth - The company has seen a significant increase in operating revenue compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., as well as a notable increase in drug sales revenue [1]